To overcome the heterogeneity of TAMs, VSIG4 and SPP1 were simultaneously inhibited and we found a synergic anti-tumor effect against ATC, highlighting targeting VSIG4-SPP1 axis as an emerging target for cancer immunotherapy. This evidence concerns the gene VSIG4 and neoplasm.